Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Solifenacin Succinate Tablets, 5 mg and 10 mg, a generic version of Vesicare® Tablets, 5 mg and 10 mg1, of Astellas Pharma US, Inc.
According to IQVIATM sales data for the 12 month period ending March 2019, the Vesicare® Tablets, 5 mg and 10 mg market2 achieved annual sales of approximately $942.7 million*.
Glenmark's current portfolio consists of 154 products authorized for distribution in the U.S. marketplace and 58 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.575.65 as compared to the previous close of Rs. 581.25. The total number of shares traded during the day was 29055 in over 718 trades.
The stock hit an intraday high of Rs. 594.9 and intraday low of 572.75. The net turnover during the day was Rs. 16826741.
1 All brand names and trademarks are the property of their respective owners.
2 Market includes brand and all available therapeutic equivalents
*IQVIATM National Sales Perspectives: Retail & Non-Retail, March 2019